Kisqali® is the commercial brand name of Ribociclib Tablets, an orally active CDK4/6 inhibitor developed by Novartis. It selectively inhibits cyclin-dependent kinases 4 and 6 (CDK4/6), blocking the phosphorylation of retinoblastoma (Rb) protein to arrest the cell cycle in G1…
Amaryl® is the commercial brand name of Glimepiride Tablets, an orally active sulfonylurea antidiabetic agent developed by Sanofi. It stimulates pancreatic beta cells to secrete more insulin, thereby lowering blood glucose levels. Main IndicationsTreatment of type 2 diabetes mellitus in…
Yunzhi® is the commercial brand name of Colchicine Tablets, an orally active anti-inflammatory agent developed by Yunnan Phytopharmaceutical Co., Ltd. It inhibits microtubule polymerization, thereby suppressing neutrophil migration, adhesion, and degranulation, and reducing inflammatory responses. Main IndicationsPrevention and treatment of…
Zhuoqing® is the commercial brand name of Spectinomycin Hydrochloride for Injection, an injectable aminocyclitol antibiotic developed by Shandong Lukang Pharmaceutical. It inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, exerting bactericidal activity against susceptible pathogens. Main IndicationsTreatment…
Jascayd® is the commercial brand name of Nerandomilast Tablets, an orally active selective phosphodiesterase 4 (PDE4) inhibitor. It exerts anti-inflammatory effects by increasing intracellular cyclic adenosine monophosphate (cAMP) levels, thereby modulating inflammatory cell function. Main IndicationsTreatment of moderate to severe…
Xiangerkang® is the Chinese commercial brand name of Methyldopa Tablets, an orally active centrally acting antihypertensive agent. It acts as a false neurotransmitter precursor, stimulating central α₂-adrenergic receptors to reduce sympathetic outflow, thereby lowering blood pressure. Main IndicationsTreatment of hypertension,…
Orpathys® is the commercial brand name of Savolitinib Tablets, an orally selective c-Met inhibitor developed by Hutchison MediPharma and AstraZeneca. It blocks the c-Met/HGF signaling pathway, inhibiting tumor cell proliferation, invasion, and angiogenesis driven by c-Met aberrations. Main IndicationsTreatment of…
GaoruiZhe® is the commercial brand name of Golidocitinib Capsules, an orally active JAK1 inhibitor developed by Dizal. It selectively inhibits Janus kinase 1 (JAK1), blocking JAK-STAT signaling pathways to suppress tumor cell proliferation and survival. Main IndicationsTreatment of adult patients…
OPDIVO® is the commercial brand name of Nivolumab Injection, a fully human anti-PD-1 monoclonal antibody developed by Bristol Myers Squibb. It blocks the binding of PD-1 receptor to its ligands PD-L1 and PD-L2, restoring the anti-tumor immune activity of T…
ELUNATE® is the commercial brand name of Fruquintinib Capsules, an orally active VEGFR tyrosine kinase inhibitor developed by Hutchison MediPharma and licensed to Eli Lilly. It selectively inhibits vascular endothelial growth factor receptors (VEGFR1, 2, 3), blocking tumor angiogenesis and…